Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV
Free accessCase reportFirst published online August, 2017
Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV
We report a case of therapeutic drug monitoring guided raltegravir use for the prevention of vertical HIV transmission in a premature neonate born to a woman living with perinatally acquired HIV and documented resistance to multiple HIV drugs. Maternal viral load was above 1,000 copies/ml at delivery. This case demonstrates delayed raltegravir elimination in a neonate born at 33 weeks gestational age and a need for less frequent raltegravir dosing than is used in older infants and children.
References
1.
BadellM.L., KachikisA., HaddadL.B., NguyenM.L., LindsayM.Comparison of pregnancies between perinatally and sexually HIV-infected women: an observational study at an urban hospital.Infect Dis Obstet Gynecol2013; 2013: 301763.
KrekelsE.H., DanhofM., TibboelD., KnibbeC.A.Ontogeny of hepatic glucuronidation; methods and results.Curr Drug Metab2012; 13: 728–743.
4.
KawadeN., OnishiS.The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver.Biochem J1981; 196: 257–260.
5.
ClarkeD.F., AcostaE.P., RizkM.L.Raltegravir pharmacokinetics in neonates following maternal dosing.J Acquir Immune Defic Syndr2014; 67: 310–315.
6.
IMPAACT P1097.Raltegravir pharmacokinetics and safety in neonates. Protocol Version 2.0 (22 January 2014). (Accessed 29 September 2016.) Available from http://www.impaactnetwork.org/studies/P1097.asp.
7.
Stanford University HIV Drug Resistance Database.Version 8.1. (Updated 23 September 2016. Accessed 28 September 2016.) Available from https://hivdb.stanford.edu.
8.
LauE., BrophyJ., SamsonL.Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission.J Acquir Immune Defic Syndr2017; 74: 493–498.
9.
de Vries-SluijsT.E., DielemanJ.P., ArtsD.Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.Clin Pharmacokinet2003; 42: 599–605.
10.
Letter of Amendment #2 for: IMPAACT P1110.A Phase I trial to evaluate the safety and pharmacokinetics of raltegravir in HIV-1-exposed neonates at high risk of acquiring HIV-1 infection. Letter of Amendment Date: 30 June 2015. (Accessed 28 September 2016.) Available from http://impaactnetwork.org/studies/P1110.asp.
11.
RizkM.L., HangY., LuoW.L.Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.Antimicrob Agents Chemother2012; 56: 3101–3106.
12.
HegaziA., Mc KeownD., DoerholtK.Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates.AIDS2012; 26: 2421–2423.
13.
Clavel-OsorioC., CazassusF., StegmannS.One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.Antimicrob Agents Chemother2013; 57: 6393–6394.
Liverpool Drug Interactions Group, University of Liverpool.Nevirapine PK fact sheet. Liverpool, United Kingdom. (Updated March 2016. Accessed 30 September 2016.) Available from http://www.hiv-druginteractions.org.
16.
SchalkwijkS., ColbersA., KonopnickiD.First reported use of elvitegravir and cobicistat during pregnancy.AIDS2016; 30: 807–808.
